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To investigate whether low-dose mitotane (up to 2 g/day) could be a temporary
therapeutic alternative to transsphenoidal surgery (TSS) in pediatric Cushing’s
disease (CD). Twenty-eight patients with CD aged 12.2 years (± 2.2) were referred to
our center. We compared nine patients treated with mitotane alone for at least 6
months to 13 patients cured after surgery. Primary outcomes were changes in growth
velocity, BMI and pubertal development. The following results were obtained: (1)
Mitotane improved growth velocity z-scores (−3.8 (±0.3) vs −0.2 (±0.6)), BMI z-
scores (2.1 (±0.5) vs 1.2 (±0.5) s.d.) and pubertal development. After 1 year on
mitotane, the mean BMI z-score was not significantly different in both groups of
patients. (2) Control of cortisol secretion was delayed and inconsistent with mitotane
used as monotherapy. (3) Side effects were similar to those previously reported,
reversible and dose dependent: unspecific digestive symptoms, concentration or
memory problems, physical exhaustion, adrenal insufficiency and hepatitis. (4) In one
patient, progressive growth of a pituitary adenoma was observed over 40 months of
mitotane treatment, allowing selective adenomectomy by TSS. In conclusions, low-
dose mitotane can restore growth velocity and pubertal development and decrease
BMI in children with CD, even without optimal control of cortisol secretion. It may
promote pituitary tumor growth thus facilitating second-line TSS. However, given its
possibly life-threatening side effects (transient adrenal insufficiency and hepatitis),
and in the absence of any reliable follow-up procedures, this therapy may be difficult
to manage and should always be initiated and monitored by specialized teams.
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